Introduction:
The Almac Group plans to invest US$ 84.7 million (£80 million) in building new extensive manufacturing, production, and diagnostic laboratory facilities in Craigavon, Northern Ireland.
Features:
The first of these two major projects is a state-of-the-art multi-product Good Manufacturing Practise (GMP) facility covering an impressive 100,000 square feet.
This Centre of Excellence for manufacturing will house various essential components, including a custom-designed dispensary area, multiple production suites, process equipment wash facilities, and a lineside warehouse for storage at different temperature levels (ambient, refrigerated, and frozen).
The primary focus of this new facility will be to support the production of solid oral dose products, complementing Almac's existing capabilities in this area.
The facility's expansion will not only increase existing manufacturing capabilities but also offer additional capacity to accommodate more strategic production contracts.
The second project is a four- storey diagnostic development and manufacturing centre, spanning 40,000 square feet.
The new facility will empower to broaden its assay development capabilities and to manufacture and distribute companion diagnostic (CDx) kits on a commercial scale.
The construction of these two substantial facilities will create over 550 job opportunities, encompassing a variety of roles, both in laboratory and non-laboratory positions.
The facilities are projected to become operational by the third quarter of 2024.
Specifications:
Name Almac Group
Type New Construction
Budget US$ 84.7 million (£80 million)
Year 2024
